BioArctic AB (publ) (BIOA-B.ST)
SEK 170.0
(-0.93%)
SEK 170.0
(-0.93%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -606.58 Million SEK | 23.73% |
| 2022 | -795.34 Million SEK | 4.47% |
| 2021 | -832.52 Million SEK | 14.98% |
| 2020 | -979.17 Million SEK | 9.79% |
| 2019 | -1.08 Billion SEK | -18.33% |
| 2018 | -917.3 Million SEK | 17.39% |
| 2017 | -1.11 Billion SEK | -60.33% |
| 2016 | -692.53 Million SEK | -508.38% |
| 2015 | -113.83 Million SEK | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -429.97 Million SEK | 11.66% |
| 2024 Q1 | -486.71 Million SEK | 19.76% |
| 2023 Q1 | -1.09 Billion SEK | -38.06% |
| 2023 Q4 | -606.58 Million SEK | 12.69% |
| 2023 FY | -606.58 Million SEK | 23.73% |
| 2023 Q3 | -694.73 Million SEK | 32.94% |
| 2023 Q2 | -1.03 Billion SEK | 5.65% |
| 2022 Q2 | -739.55 Million SEK | 5.99% |
| 2022 Q1 | -786.68 Million SEK | 5.51% |
| 2022 Q4 | -795.34 Million SEK | 6.76% |
| 2022 Q3 | -852.99 Million SEK | -15.34% |
| 2022 FY | -795.34 Million SEK | 4.47% |
| 2021 FY | -832.52 Million SEK | 14.98% |
| 2021 Q1 | -941.03 Million SEK | 3.89% |
| 2021 Q3 | -873.71 Million SEK | 4.02% |
| 2021 Q2 | -910.33 Million SEK | 3.26% |
| 2021 Q4 | -832.52 Million SEK | 4.71% |
| 2020 Q2 | -1.02 Billion SEK | 2.44% |
| 2020 FY | -979.17 Million SEK | 9.79% |
| 2020 Q4 | -979.17 Million SEK | 3.46% |
| 2020 Q3 | -1.01 Billion SEK | 1.24% |
| 2020 Q1 | -1.05 Billion SEK | 3.02% |
| 2019 Q3 | -1.14 Billion SEK | 3.93% |
| 2019 Q4 | -1.08 Billion SEK | 4.93% |
| 2019 FY | -1.08 Billion SEK | -18.33% |
| 2019 Q1 | -1.22 Billion SEK | -33.44% |
| 2019 Q2 | -1.18 Billion SEK | 2.91% |
| 2018 Q4 | -917.3 Million SEK | 9.04% |
| 2018 Q3 | -1 Billion SEK | 3.19% |
| 2018 FY | -917.3 Million SEK | 17.39% |
| 2018 Q1 | -1.07 Billion SEK | 2.85% |
| 2018 Q2 | -1.04 Billion SEK | 3.43% |
| 2017 Q3 | -590.67 Million SEK | 5.05% |
| 2017 Q4 | -1.11 Billion SEK | -87.98% |
| 2017 Q1 | 692.53 Million SEK | 200.0% |
| 2017 FY | -1.11 Billion SEK | -60.33% |
| 2017 Q2 | -622.06 Million SEK | -189.82% |
| 2016 Q4 | -692.53 Million SEK | 0.0% |
| 2016 FY | -692.53 Million SEK | -508.38% |
| 2016 Q1 | 113.83 Million SEK | 0.0% |
| 2015 FY | -113.83 Million SEK | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | -50.02 Million SEK | -1112.667% |
| Ziccum AB (publ) | -2.13 Million SEK | -28285.026% |
| Modus Therapeutics Holding AB (publ) | -19.06 Million SEK | -3082.518% |
| Sprint Bioscience AB (publ) | -49.93 Million SEK | -1114.78% |
| Mendus AB (publ) | -96.29 Million SEK | -529.933% |
| Genovis AB (publ.) | -43.94 Million SEK | -1280.46% |
| Intervacc AB (publ) | -88.16 Million SEK | -588.054% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 20.51 Million SEK | 3057.523% |
| Active Biotech AB (publ) | -33.2 Million SEK | -1727.072% |
| Magle Chemoswed Holding AB (publ) | 53.22 Million SEK | 1239.71% |
| Bio-Works Technologies AB (publ) | -39.38 Million SEK | -1440.267% |
| Aptahem AB (publ) | 2.9 Million SEK | 20954.681% |
| Vicore Pharma Holding AB (publ) | -333.62 Million SEK | -81.82% |
| Kancera AB (publ) | -45.69 Million SEK | -1227.558% |
| Infant Bacterial Therapeutics AB (publ) | -329.06 Million SEK | -84.337% |
| Fluicell AB (publ) | -2.76 Million SEK | -21853.963% |
| Saniona AB (publ) | 40.44 Million SEK | 1599.711% |
| Lipigon Pharmaceuticals AB (publ) | -31.92 Million SEK | -1799.922% |
| Biovica International AB (publ) | -58.73 Million SEK | -932.719% |
| Spago Nanomedical AB (publ) | -45.21 Million SEK | -1241.504% |
| AcouSort AB (publ) | -23.98 Million SEK | -2428.925% |
| Xintela AB (publ) | -7.8 Million SEK | -7667.806% |
| Abliva AB (publ) | -57.24 Million SEK | -959.727% |
| Egetis Therapeutics AB (publ) | -194.7 Million SEK | -211.55% |
| Karolinska Development AB (publ) | -82.2 Million SEK | -637.924% |
| OncoZenge AB (publ) | -12.62 Million SEK | -4703.896% |
| Amniotics AB (publ) | -5.63 Million SEK | -10670.384% |
| 2cureX AB (publ) | -13.4 Million SEK | -4425.763% |
| CombiGene AB (publ) | -101.44 Million SEK | -497.977% |
| Asarina Pharma AB (publ) | -2.16 Million SEK | -27969.783% |
| Calliditas Therapeutics AB (publ) | 5.4 Million SEK | 11333.111% |
| Camurus AB (publ) | -1.16 Billion SEK | 47.947% |
| Corline Biomedical AB | -17.01 Million SEK | -3465.648% |
| IRLAB Therapeutics AB (publ) | -83.74 Million SEK | -624.345% |
| Isofol Medical AB (publ) | -138.14 Million SEK | -339.086% |
| I-Tech AB | -83.26 Million SEK | -628.529% |
| Hansa Biopharma AB (publ) | 134.7 Million SEK | 550.298% |
| Cyxone AB (publ) | -16.67 Million SEK | -3538.8% |
| ExpreS2ion Biotech Holding AB (publ) | -55.88 Million SEK | -985.402% |
| Biosergen AB | -1.88 Million SEK | -32113.914% |
| Cantargia AB (publ) | -139.74 Million SEK | -334.062% |
| NextCell Pharma AB | -46.79 Million SEK | -1196.388% |
| Xspray Pharma AB (publ) | -129.49 Million SEK | -368.426% |
| Elicera Therapeutics AB (publ) | -29.38 Million SEK | -1964.421% |
| Nanologica AB (publ) | -9.38 Million SEK | -6361.312% |
| SynAct Pharma AB | -61.75 Million SEK | -882.201% |
| Annexin Pharmaceuticals AB (publ) | -21.41 Million SEK | -2732.538% |
| Stayble Therapeutics AB (publ) | -13.22 Million SEK | -4485.227% |
| LIDDS AB (publ) | -13.51 Million SEK | -4389.254% |
| Lipum AB (publ) | -8.46 Million SEK | -7065.836% |
| BioInvent International AB (publ) | -236.3 Million SEK | -156.698% |
| Alzinova AB (publ) | -21.22 Million SEK | -2757.759% |
| Oncopeptides AB (publ) | -66.92 Million SEK | -806.438% |
| Pila Pharma AB (publ) | -5.18 Million SEK | -11608.114% |
| Guard Therapeutics International AB (publ) | -83.74 Million SEK | -624.362% |
| Scandinavian ChemoTech AB (publ) | -923 Thousand SEK | -65619.177% |
| Simris Alg AB (publ) | 85.07 Million SEK | 813.004% |
| Diamyd Medical AB (publ) | -82.08 Million SEK | -638.966% |
| Xbrane Biopharma AB (publ) | 166.07 Million SEK | 465.245% |
| Ascelia Pharma AB (publ) | -20.79 Million SEK | -2817.27% |
| Diagonal Bio AB (publ) | -2.97 Million SEK | -20310.094% |